Twitter-Delivered CME/CE on
Chronic Kidney Disease from @ckd_ce
The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. This is particularly important in the care of patients with or at risk for CKD, as this has become a multidisciplinary and interprofessional focus. Kidney health is now linked not only pathophysiologically but also by treatment strategies that target diverse cardiovascular outcomes as well as renal health. These issues are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.
Our Tweetorials
Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.
The (Busy!) Year in Review: The Emergence of Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension in 2025
2) During 2025 you learned about these developments from @PamTaubMD & @edgarvlermamd 🇵🇭. You can still earn 🆓credit at https://t.co/k9JQR6Jis4....
The Nephrology Community’s Reception of New Phase 3 Data on Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension at ESC2025
2) You've already seen those data w/@PamTaubMD & u can still earn 🆓credit by checking out https://t.co/7UAKU80flQ. Now we take a look at...
New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor
2) Our expert faculty is Pam R Taub MD @PamTaubMD, #Cardiologist & Prof Medicine @UCSDMedSchool 🇺🇸. She will be reporting & commenting on...
The Importance to Cardiorenal Outcomes of Effective Blood Pressure Control and the Pathophysiologic Role of Aldosterone Dysregulation
2) This program is intended for #HCPs & is supported by an unrestricted educational grant from AstraZeneca. Statement of accreditation, faculty...
Current Management of Difficult-to-Control Hypertension
2) We are pleased to welcome a new & esteemed guest faculty member, Alta Schutte PhD @alta_schutte, Professor of Cardiovascular Medicine from...
IgAN Update Fall 2024
2) Statement of accreditation and author disclosures can be found at https://t.co/PHlIpplEO4. No industry funding was provided for this program,...
New Data on GLP-1RAs: The FLOW Study
2) We welcome returning faculty Dilushi Wijayaratne @Dilushiwijay, Consultant #Nephrologist & Lecturer, & @ISNEducation #SoMe team member...
Early, Optimal Management of CKD and Cardiorenal Disease to Prevent Disease Progression and Improve Outcomes
2) The program is intended for #HCPs & is supported by an independent educational grant from Bayer. Statement of accreditation and faculty...
The Conundrum of Alkali Therapy in Calcium Phosphate Stone Formers
2a) Welcome to a?#accredited #tweetorial brought to you by the collaboration of @ckd_ce & @KIReports.Our guest author is Ali W. Rizvi @AWRizviDO...
Long-Term Response to Rituximab vs Tacrolimus in Children with Steroid-Dependent Nephrotic Syndrome
2) Our returning guest author is Melvin Chan @MChanMD from @CUPedsNeph.Our topic for ?CE/#CME : Early Rituximab as an Add-On Therapy in Children...
@CKD_CE on Twitter
Your only source for ACCREDITED SoMe-delivered
serialized professional cardiometabolic education. Physicians, nurses, pharmacists–come one, come all!
On Twitter at @ckd_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME. Programs are presented by expert faculty in engaging and fully interactive format. Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.